Tracing the Path from Obesity to Diabetes: How S-Allyl Cysteine Shapes Metabolic Health

TL;DR

This paper explores how S-allyl cysteine, a compound from black garlic, may help prevent and manage metabolic syndrome and its complications.

Contribution

The paper highlights the novel potential of S-allyl cysteine as a nutraceutical for addressing multiple aspects of metabolic syndrome.

Findings

S-allyl cysteine reduces lipid accumulation and insulin resistance in preclinical studies.

It improves endothelial dysfunction and gut microbiota alterations through various mechanisms.

SAC shows antioxidant and anti-inflammatory effects relevant to metabolic syndrome.

Abstract

Background: Metabolic Syndrome (MetS) is a multifactorial condition characterized by insulin resistance, dyslipidemia, hypertension, and abdominal obesity, which collectively increase the risk of type 2 diabetes mellitus and cardiovascular diseases. Lifestyle modification represents the first-line strategy in its management, whereas pharmacological interventions are complex and typically require long-term polypharmacotherapy. In this context, natural bioactive compounds with pleiotropic effects are gaining increasing attention. Among these, S-allyl cysteine (SAC), the major sulfur-containing compound derived from black garlic, has been identified as a promising candidate due to its well-documented antioxidant and anti-inflammatory properties. Methods: This narrative review examines the pathophysiological mechanisms underlying MetS and summarizes current evidence on the protective role of SAC against key pathological features of this condition, including oxidative stress, inflammation, glucose and lipid dysmetabolism, endothelial dysfunction, and gut microbiota alterations. Results: Preclinical studies indicate that SAC counteracts lipid accumulation, insulin resistance, endothelial dysfunction, and gut dysbiosis through multiple mechanisms, including hydrogen sulfide release, reactive oxygen species scavenging, inhibition of advanced glycation end products, and modulation of metabolic pathways. Conclusions: SAC emerges as a promising nutraceutical for the prevention and management of MetS and its complications. This underscores the broader relevance of nutraceuticals as promising tools in mitigating metabolic dysfunctions and reducing the burden of cardiometabolic diseases.

Figures